Gene Expression Profile Improves ID of High-Risk Melanoma

This article originally appeared here.
Share this content:
Gene Expression Profile Improves ID of High-Risk Melanoma
Gene Expression Profile Improves ID of High-Risk Melanoma

THURSDAY, April 27, 2017 (HealthDay News) -- A validated 31-gene expression profile (GEP) signature improves identification of patients with melanoma at high risk of metastasis when used in combination with the American Joint Committee on Cancer (AJCC) outcome prediction tool, according to a study published in the May issue of the Journal of the American Academy of Dermatology.

Laura K. Ferris, M.D., Ph.D., from the University of Pittsburgh Medical Center, and colleagues compared the accuracy of the GEP in combination with risk determined using the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool for 205 stage I/II cutaneous melanomas.

The researchers found that there was significant risk classification of distant metastasis-free and overall survival (hazard ratio, range 3.2 to 9.4) for both tools in Cox univariate analysis. Using a five-year overall survival cutoff of 79 percent, 43 cases (21 percent) had discordant GEP and AJCC classification. Of the 13 deaths in that group, 11 were predicted as high-risk by GEP but low-risk by AJCC.

"The GEP provides valuable prognostic information and improves identification of high-risk melanomas when used together with the AJCC online prediction tool," conclude the authors.

Several authors report financial ties to Castle Biosciences, which provided financial compensation to the centers that contributed cutaneous melanoma tissue to the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths